
Polina Weitzenfeld

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/978215/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	71
2	Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways. Journal of Clinical Investigation, 2019, 129, 3952-3962.	8.2	38
3	Chemokine axes in breast cancer: factors of the tumor microenvironment reshape the CCR7-driven metastatic spread of luminal-A breast tumors. Journal of Leukocyte Biology, 2016, 99, 1009-1025.	3.3	30
4	Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells. Oncotarget, 2016, 7, 81123-81143.	1.8	23
5	The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Letters, 2014, 352, 36-53.	7.2	124
6	Progression of Luminal Breast Tumors Is Promoted by Ménage à Trois between the Inflammatory Cytokine TNF <i>α</i> and the Hormonal and Growth-Supporting Arms of the Tumor Microenvironment. Mediators of Inflammation, 2013, 2013, 1-19.	3.0	17
7	The Versatile World of Inflammatory Chemokines in Cancer. , 2013, , 135-175.		1
8	Epidermal Growth Factor and Estrogen Act by Independent Pathways to Additively Promote the Release of the Angiogenic Chemokine CXCL8 by Breast Tumor Cells. Neoplasia, 2011, 13, 230-243.	5.3	25
9	Inflammatory mediators in breast cancer: Coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer, 2011, 11, 130.	2.6	229